Business Wire

CORRECTING and REPLACING PHOTO Zynga Celebrates Bugatti’s 110th Anniversary with Special CSR Racing 2 Event Series

4.12.2019 20:27:00 EET | Business Wire | Press release

Share

Please replace the photo with the accompanying corrected photo.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191204005025/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Zynga Celebrates Bugatti’s 110th Anniversary with Special CSR Racing 2 Event Series (Photo: Business Wire)

The release reads:

ZYNGA CELEBRATES BUGATTI’S 110TH ANNIVERSARY WITH SPECIAL CSR RACING 2 EVENT SERIES

Players Can Race and Collect Exclusive Bugatti-Engineered Hyper Sports Cars in Game

Today, Zynga Inc. (Nasdaq: ZNGA), a global leader in interactive entertainment, is launching an event series in partnership with the hyper sports car manufacturer Bugatti in the hit mobile drag racing game, CSR Racing 2 (CSR2). The event series, which celebrates Bugatti’s 110th anniversary, will give players the opportunity to collect and compete with the world’s most powerful and exclusive hyper sports cars in CSR2.

“Bugatti is one of the most iconic and revered car manufacturers in the world, and we are truly honored to celebrate such an important milestone with them,” said Julian Widdows, Vice President of CSR2. “Our team worked tirelessly to make sure everything from the cars’ sleek forms to their powerful engines is authentically represented in the game. This is the closest an aficionado can come to owning a Bugatti without actually buying one.”

The series showcases 24 different Bugatti cars, three of which are available exclusively in CSR2. Players can view the cars in augmented reality, giving them the experience of sitting in the driver’s seats of the most desirable hyper sports cars ever designed. The integration has seven different events over an eight-week period, and will be highlighted in a continued beta version of CSR2’s new player-versus-player feature, Showdown.

CSR2 Bugatti Exclusives:

  • Chiron Super Sport 300: the first series production car to break the magical 300 miles per hour barrier
  • La Voiture Noire: a one-off one grand tourisme masterpiece
  • Centodieci: the newly released homage to the original modern-day super sports car, EB110

“Interactive entertainment is a main driver for today’s young generation’s enthusiasm for cars and a great way to stay in touch with fans around the world,” said Bugatti President, Stephan Winkelmann. “We are very excited that through this partnership, our enthusiasts have the opportunity to experience all of our latest exclusive Bugatti hyper sports cars in CSR2.”

Every aspect of the 24 Bugatti cars, from the grills to the paint color, dashboard finish and stitching, has been meticulously recreated in CSR2 to mirror the real hyper sports cars. Players can explore the cars by tapping special points to trigger handcrafted, bespoke animations, allowing them to open doors, pop the hoods, inspect the engine bays, extend the spoilers and more.

CSR2 is available to download for free on the App Store as well as the Google Play Store. For more information about CSR2, visit the game’s community channels on Facebook, Twitter, Instagram, and YouTube.

Editor’s Note - To view the supporting assets for CSR Racing 2 (CSR2), please click here: https://app.box.com/s/56junq0iv8ibm2dx0mqfo8hpkd7qlk64

About Zynga Inc.

Zynga is a global leader in interactive entertainment with a mission to connect the world through games. To date, more than one billion people have played Zynga’s franchises including CSR Racing™, Empires & Puzzles™, Merge Dragons!™, Words With Friends™ and Zynga Poker™. Zynga’s games are available in more than 150 countries and are playable across social platforms and mobile devices worldwide. Founded in 2007, the company is headquartered in San Francisco with locations in the U.S., Canada, U.K., Ireland, India, Turkey and Finland. For more information, visit www.zynga.com or follow Zynga on Twitter and Facebook.

About Bugatti

Bugatti Automobiles S.A.S. manufactures the world's most powerful, fastest, most exclusive and luxurious production hyper sports car. Since its foundation in 1909, the French luxury brand has been based on and off in Molsheim, Alsace. The Veyron was made there between 2005 and 2015, the first modern-day hyper sports car, of which 450 vehicles were built by hand. Since autumn 2016, the staff in Molsheim have been producing the Chiron1 models.

With an output of 1,500 hp, which has never before been achieved by production vehicles, a torque of 1,600 newton metres at 2,000 to 6,000 rpm and numerous technical innovations, the Chiron1 has been setting new standards in automotive engineering ever since.

In 2017, Bugatti delivered 70 vehicles to customers, by 2018 this had increased to 76. More than 80 vehicles are set to be delivered to customers in 2019. Bugatti has announced the construction of 500 models – currently only 100 Chiron can be ordered. Production of the Divo2, a vehicle optimised for lateral acceleration, will follow soon.

Bugatti has been part of the Volkswagen Group since 1998 and employs more than 300 people. The majority of these work in Molsheim in Alsace. With 37 dealers and service partners in 18 countries in Europe, North America, the Middle East and Asia-Pacific, Bugatti is a global player.

1 Fuel consumption, l/100km: urban 35.2 / extra-urban 15.2 / combined 22.5; combined CO2 emissions, g/km: 516; efficiency class: G

2 Fuel consumption, l/100km: not subject to Directive 1999/94/EC as overall type approval is currently not yet available

Forward Looking Statement

This press release contains forward-looking statements, relating to, among other things, the release of future CSR Racing 2 game features and events. Forward-looking statements often include words such as "outlook," "projected," “planned,” "intends," "will," "anticipate," "believe," "target," "expect," and statements in the future tense are generally forward-looking. The achievement or success of the matters covered by such forward-looking statements involves significant risks, uncertainties, and assumptions. Undue reliance should not be placed on such forward-looking statements, which are based on information available to us on the date hereof. We assume no obligation to update such statements. More information about these risks, uncertainties, and assumptions are or will be described in greater detail in our public filings with the Securities and Exchange Commission (the "SEC"), copies of which may be obtained by visiting our Investor Relations web site at http://investor.zynga.com or the SEC's web site at www.sec.gov

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Zynga Media Contact:
Kenny Johnston
kjohnston@zynga.com | (602) 999-1890

Or

Bugatti Automobiles S.A.S. Contact:
Tim Bravo
Head of Communications
Mobile: +33 640 151969
Email: tim.bravo@bugatti.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye